Table 3.
AUC for a Number of CPX Variables
| HFrEF Versus COPD (Excluding Mixed) | HFrEF Versus Healthy Adults | COPD Versus Healthy Adults | |
|---|---|---|---|
| BR, % | 0.91 (0.84–0.98) | 0.58 (0.49–0.68) | 0.96 (0.94–0.99) |
| Breathing reserve at AT, % | 0.89 (0.80–0.98) | — | — |
| OUES, % predicted | 0.87 (0.79–0.96) | 0.89 (0.82–0.95) | 0.52 (0.39–0.66) |
| OUES/kg | 0.84 (0.75–0.93) | 0.89 (0.84–0.95) | 0.59 (0.45–0.72) |
| O2 pulse, ml/beat | 0.80 (0.69–0.91) | 0.61 (0.51–0.71) | 0.89 (0.84–0.95) |
| Peak oxygen saturations, % | 0.79 (0.68–0.90) | — | — |
| DP, mm Hg beats/min | 0.78 (0.67–0.90) | 0.91 (0.86–0.95) | 0.75 (0.65–0.84) |
| RER at peak | 0.75 (0.62–0.88) | — | — |
| VO2/WR slope | 0.68 (0.54–0.83) | 0.70 (0.60–0.81) | 0.52 (0.38–0.66) |
| HR at peak, beats/min | 0.68 (0.55–0.81) | 0.80 (0.73–0.88) | 0.70 (0.60–0.80) |
| Peak VO2, ml/min | 0.66 (0.52–0.79) | 0.82 (0.75–0.88) | 0.90 (0.84–0.95) |
| OUEP | 0.65 (0.51–0.80) | — | — |
| OUES | 0.65 (0.51–0.78) | 0.83 (0.76–0.90) | 0.71 (0.60–0.83) |
| AT, ml/min | 0.65 (0.49–0.80) | 0.67 (0.58–0.76) | 0.79 (0.69–0.89) |
| VE/VCO2 slope 2 | 0.64 (0.48–0.79) | — | — |
| HR/VO2 slope | 0.63 (0.49–0.77) | 0.50 (0.39–0.62) | 0.65 (0.54–0.76) |
| VE/VCO2 ratio AT | 0.59 (0.42–0.77) | 0.85 (0.79–0.91) | 0.88 (0.80–0.97) |
| VE/VCO2 slope 1 | 0.57 (0.42–0.73) | 0.92 (0.88–0.96) | 0.77 (0.65–0.90) |
| AT, % of predicted peak VO2 | 0.56 (0.40–0.72) | 0.72 (0.62–0.82) | 0.68 (0.54–0.83) |
| O2 pulse, % predicted | 0.56 (0.41–0.71) | 0.79 (0.70–0.88) | 0.82 (0.72–0.92) |
| VE/VCO2 ratio nadir | 0.54 (0.38–0.70) | — | — |
| Peak VO2, ml/min/kg | 0.54 (0.38–0.69) | 0.89 (0.83–0.94) | 0.83 (0.74–0.91) |
| Circ power, mm Hg ml/min | 0.53 (0.37–0.68) | 0.90 (0.86–0.95) | 0.88 (0.81–0.94) |
| Peak VO2, % predicted | 0.51 (0.36–0.66) | 0.91 (0.86–0.96) | 0.90 (0.82–0.98) |
| PETCO2 at AT, mm Hg | 0.51 (0.32–0.69) | 0.73 (0.64–0.82) | 0.71 (0.58–0.85) |
Values are area under the curve (AUC) calculated following 3 receiver-operating characteristic curve analyses: the primary analysis was patients with heart failure versus patients with COPD (excluding mixed disease); patients with heart failure versus healthy matched controls from the SHIP cohort; and patients with COPD versus healthy matched controls from the SHIP (Study of Health In Pomerania) cohort. The AUC does not indicate the direction of the discrimination. The variables are ordered by the AUC for the primary analysis and grouped as good (AUC: >0.8, top 4 variables), moderate (AUC: >0.70, next 4 variables), and poor discrimination (AUC: ≤0.70, remaining variables).